Effect of PPAR-γ Agonist on Adiponectin Levels in the Metabolic Syndrome: Lessons From the High Fructose Fed Rat Model | Zendy

Yehonatan Sharabi | Zendy; Mor OronHerman | Zendy; Yehuda Kamari | Zendy; Irit Avni | Zendy; Edna Peleg | Zendy; Z. Shabtay | Zendy; Ehud Grossman | Zendy; Ari Shamiss | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of PPAR-γ Agonist on Adiponectin Levels in the Metabolic Syndrome: Lessons From the High Fructose Fed Rat Model

Author(s) -

Yehonatan Sharabi,

Mor OronHerman,

Yehuda Kamari,

Irit Avni,

Edna Peleg,

Z. Shabtay,

Ehud Grossman,

Ari Shamiss

Publication year - 2007

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1016/j.amjhyper.2006.08.002

Subject(s) - rosiglitazone , endocrinology , medicine , adiponectin , fructose , metabolic syndrome , insulin , insulin resistance , agonist , diabetes mellitus , chemistry , receptor , biochemistry

The health hazard of the metabolic syndrome (MS) is increasing, yet there is no effective pharmacologic treatment to this entity as a whole. Recently, hypoadiponectinemia was found to play an important role in the development of MS. We studied the effect of the PPAR-gamma agonist rosiglitazone on adiponectin and the metabolic profile in the fructose-induced hypertensive, hyperinsulinemic, hypertriglyceridemic rat model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research